Lacril

Drug Overview

In the field of Ophthalmology, the maintenance of the ocular surface is paramount to ensuring visual clarity and patient comfort. Lacril is a primary therapeutic agent within the Drug Class known as Ocular Lubricants. It is formulated to mimic the complex nature of human tears, providing an essential shield for the cornea and conjunctiva against environmental and physiological stressors.

As a Targeted Therapy for the ocular surface, Lacril addresses the widespread clinical challenge of tear film instability. Whether caused by aging, digital eye strain, or underlying autoimmune conditions, the degradation of the tear film can lead to significant discomfort and potential surface damage. Lacril serves as a foundational treatment in managing these degenerative changes.

• Generic Name: Hypromellose (Hydroxypropyl Methylcellulose) / Polyvinyl Alcohol
• US Brand Names: Lacril, Refresh, Systane (comparative formulations)
• Route of Administration: Topical Ophthalmic Drops (Solution)
• FDA Approval Status: FDA-approved as an Over-the-Counter (OTC) ophthalmic demulcent for the temporary relief of burning and irritation due to dryness of the eye.
  
  Learn how Lacril provides soothing everyday relief as a high-quality artificial tear formulation for persistent dry eye symptoms.

What Is It and How Does It Work? (Mechanism of Action)

To understand the efficacy of Lacril, one must first appreciate the three-layer structure of the natural tear film: the lipid (oil) layer, the aqueous (water) layer, and the mucin (sticky) layer. Dry eye symptoms occur when one or more of these layers fail, leading to rapid tear evaporation or poor wetting of the ocular surface.

Lacril functions at the molecular level primarily as a demulcent and viscosity-enhancing agent. Its mechanism involves:

1. Mucomimetic Action: The active ingredients in Lacril, such as Hypromellose, act as a substitute for the natural mucin layer. Mucins are responsible for making the hydrophobic (water-repelling) corneal epithelium hydrophilic (water-loving). By binding to the corneal surface, the polymers in Lacril ensure that the aqueous portion of the tears spreads evenly across the eye.
2. Increased Residence Time: High-molecular-weight polymers increase the viscosity of the solution. This allows the drop to remain on the ocular surface for an extended period rather than being immediately drained through the nasolacrimal duct. This sustained hydration is critical for healing epithelial micro-erosions.
3. Surface Tension Reduction: The formulation reduces the surface tension of the tear film. This stabilizes the interface between the air and the eye, preventing the formation of “dry spots” on the cornea that cause the sensation of grittiness and sharp pain.
4. Osmotic Balance: Modern formulations of Lacril are often designed to be hypotonic or isotonic. In Dry Eye Disease (DED), tears become hyperosmolar (salty), which inflames the surface cells. Lacril helps dilute this saltiness, restoring a healthy physiological balance and reducing inflammation at the cellular level.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Lacril is the temporary relief of symptoms associated with Dry Eye Disease (DED). This includes the alleviation of burning, stinging, “foreign body sensation,” and dryness caused by environmental factors (such as wind or air conditioning) or ocular health conditions.

Other Approved & Off-Label Uses

While primarily a lubricant, Lacril is versatile in various clinical and post-surgical ophthalmic scenarios:

• Primary Ophthalmology Indications:
  • Keratoconjunctivitis Sicca (KCS): Chronic management of severe dry eye to prevent corneal scarring and maintain visual acuity.
  • Post-Operative Recovery: Used frequently after LASIK or Cataract surgery to support the healing of the corneal epithelium.
  • Exposure Keratopathy: Treatment for patients who cannot fully close their eyelids (e.g., Bell’s Palsy or thyroid eye disease), preventing the cornea from drying out.
  • Contact Lens Discomfort: Used to re-wet the ocular surface; however, specialized Preservative-Free versions are often preferred for this sub-population.
  • Diagnostic Procedures: Used as a lubricant during gonioscopy or certain laser treatments to protect the cornea from the diagnostic lens.

Dosage and Administration Protocols

The administration of Lacril is flexible and depends largely on the severity of the patient’s symptoms. However, proper technique is essential to prevent contamination and maximize the therapeutic effect.

Indication	Standard Dose	Frequency
Mild Dry Eye	1 to 2 drops	3 to 4 times daily
Chronic/Moderate Dry Eye	1 to 2 drops	Every 2 to 4 hours or as needed
Post-LASIK Recovery	1 to 2 drops	Hourly for the first 24-48 hours
Environmental Irritation	1 to 2 drops	Single dose upon exposure

Specific Instructions:

• Hygiene: Always wash hands before use.
• Technique: Tilt the head back, pull the lower eyelid down, and instill the drop without touching the dropper tip to the eye or any other surface.
• Punctal Occlusion: Gently press the inner corner of the eye for 1 minute after instillation to increase surface absorption.
• Drop Spacing: If using other medications (e.g., Glaucoma drops), wait at least 5 minutes before applying Lacril to avoid washing out the active drug.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical research between 2020 and 2026 has shifted toward the “Ocular Surface Disease Index” (OSDI) and objective metrics like Tear Break-Up Time (TBUT).

Numerical Efficacy Data:

• Tear Film Stability: Clinical trials have shown that consistent use of Lacril can increase the TBUT by an average of 2.5 to 4 seconds, moving patients from a “severe” category to a “mild/moderate” category.
• Visual Acuity (BCVA): While Lacril does not treat refractive errors, studies show that stabilizing the tear film can improve “Functional Visual Acuity.” Patients often gain 1 to 2 letters on the ETDRS chart simply by eliminating the optical distortions caused by a dry, irregular corneal surface.
• Corneal Staining: Using fluorescein dye, researchers have documented a 30% to 50% reduction in “punctate epithelial erosions” (micro-scratches on the eye) after 4 weeks of consistent Ocular Lubricant therapy.
• Central Retinal Thickness (CRT): While Lacril does not directly affect the retina, it is critical for clear OCT imaging. Clearer surface lubrication allows for more precise CRT measurements in patients with Diabetic Macular Edema (DME).

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Lacril.

Lacril is generally regarded as extremely safe; however, the presence of preservatives in multi-dose bottles can be a factor for sensitive patients.

Common Side Effects (>10%)

• Transient Blurred Vision: Due to the viscosity of the drop, vision may be blurry for 30-60 seconds after instillation.
• Ocular Matted Lashes: Dried lubricant may cause a slight crusting on the eyelashes.
• Minor Stinging: Some patients report a brief cooling or stinging sensation upon application.

Serious Adverse Events

• Hypersensitivity: Rare allergic reactions to components like Benzalkonium Chloride (BAK) or the polymers themselves.
• Corneal Melting (Rare): Only associated with excessive use of preserved drops in eyes with severely compromised surfaces.
• Systemic Absorption: Negligible; Lacril remains localized to the ocular surface.

Management Strategies:

For patients requiring dosing more than 4-6 times per day, a Preservative-Free formulation is mandatory to prevent “preservative-induced toxicity.” Patients should monitor for increased redness or pain, which may indicate a reaction to the drop rather than the disease itself.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is investigating the role of Lacril in protecting Goblet Cell Density. Goblet cells are the biological producers of natural mucin. Recent studies suggest that by reducing surface friction, Ocular Lubricants like Lacril prevent the mechanical destruction of these cells, helping the eye maintain its natural defense system.

Generalization (Novel Delivery Systems)

The future of ocular lubrication lies in Novel Delivery Systems:

• Sustained-Release Ocular Implants: Research into tiny, biodegradable inserts placed in the lower lid that slowly release lubricant over 12 hours.
• Preservative-Free Multi-Dose Bottles: Advanced bottle designs with one-way valves that allow for sterile, preservative-free delivery without the waste of single-use vials.
• Biosimilars: While not applicable to simple lubricants, the development of “Bio-inspired” lubricants that contain growth factors to heal the corneal nerve is an active field.

Severe Disease & Surgical Integration

In end-stage Glaucoma, the chronic use of medicated drops often destroys the ocular surface. Lacril is being studied as a mandatory adjunct in these patients to improve the success rate of surgeries like trabeculectomies, as a healthy conjunctiva is necessary for a successful surgical “bleb.”

Disclaimer: These studies regarding sustained-release inserts and bio-inspired growth factors are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

A thorough baseline is required to differentiate between simple dryness and more complex diseases:

• Baseline Diagnostics: Visual Acuity, Tonometry (to rule out Glaucoma), and Slit-lamp exam.
• Ocular Imaging: Optical Coherence Tomography (OCT) of the cornea to measure epithelial thickness.
• Specialized Testing: Schirmer’s Test (measuring tear volume) and Tear Film Break-Up Time (TBUT).
• Screening: Identifying a history of Herpes Simplex Keratitis or allergies to BAK.

Monitoring and Precautions

• Vigilance: Patients using steroids alongside lubricants must be monitored for IOP spikes.
• Lifestyle:
  • UV Protection: Wearing sunglasses to reduce tear evaporation.
  • Eyelid Hygiene: Regular lid scrubs to ensure the lipid-producing glands are not blocked.
  • Blue Light: Taking “20-20-20” breaks during computer use to increase blink rate.
• Do’s and Don’ts:
  • DO use Preservative-Free vials if you use drops more than 4 times a day.
  • DO keep the bottle tip clean.
  • DON’T use “redness relief” drops (vasoconstrictors) as a substitute for lubricants.
  • DON’T ignore persistent pain or sudden vision loss.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of an ophthalmologist or other qualified health provider with any questions you may have regarding a medical condition. Use of Lacril should be based on clinical need as determined by a healthcare professional. Information regarding clinical trials is current as of the 2026 reporting period.